secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0000950170-24-082092
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia CEO Stanley Jacot resigns; CFO Schaefer promoted to CEO, Kawakami named CFO
--------------------------------------------------------------------------------

- Stanley Jacot, Jr. resigned as president, CEO, and director on July 2, 2024; cash severance $288,077 + 12-month option acceleration + COBRA through Feb 2025.
- CFO Thomas J. Schaefer appointed president and CEO effective July 5, 2024; he had been CFO since Jan 2023.
- Mark Kawakami appointed CFO effective July 5, 2024; he was VP Finance since Jan 2023; base salary $212,063.
- Separation Agreement includes general release of claims, confidentiality, and non-disparagement by Jacot.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/rkda-20240702.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-082092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer